Since semaglutide affects both appetite and digestion, it can alter how many nutrients a person consumes
Acute Gallbladder Disease: If cholelithiasis or cholecystitis are suspected, gallbladder studies are indicated (5.8)
Beyond traditional labs, emerging biomarkers may offer additional insights into fibrosis progression or regression, though they are not yet standard in all practices
Studies show patients who sustain lifestyle changes experience slower, minimal rebound compared to those who return to previous eating patterns
Weight loss achieved through semaglutide use may indirectly benefit certain digestive conditions associated with obesity, such as gastroesophageal reflux disease (GERD) or metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD), but this represents a secondary effect rather than direct gut healing
Your healthcare provider will establish a monitoring schedule tailored to your individual clinical situation, but general recommendations include specific metabolic, safety, and tolerability assessments
